Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 8/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.38 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24298509 | 0.91 | TGFBR1 (0.49) | TGFBR1ABCG2PLA2G2ASLC2A1MAPK10 | |
| SCHEMBL24095438 | 0.83 | ROCK1 (0.43) | TGFBR1 | |
| SCHEMBL24095449 | 0.82 | TGFBR1 (0.49) | TGFBR1ABCG2SLC2A1MAPK10 | |
| SCHEMBL24095386 | 0.82 | TGFBR1 (0.49) | TGFBR1ABCG2PLA2G2AKCNH2TNIK | |
| SCHEMBL24095419 | 0.82 | TGFBR1 (0.46) | TGFBR1ABCG2PLA2G2ASLC2A1MAPK10 | |
| SCHEMBL24298642 | 0.78 | MAP4K1 (0.40) | TGFBR1 | |
| SCHEMBL24095451 | 0.76 | KDM5A (0.39) | TGFBR1 | |
| SCHEMBL24095454 | 0.74 | TGFBR1 (0.78) | TGFBR1KCNH2TNIK | |
| SCHEMBL24095412 | 0.74 | ROCK1 (0.46) | TGFBR1 | |
| SCHEMBL3955188 | 0.73 | TGFBR1 (0.61) | TGFBR1ABCG2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220098171-A1 | 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS SERVING AS TGF-ßR1 KINASE INHIBITOR | JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) | 2022-03-31 | — | — | US | disclosed |
| EP-3922631-A1 | 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS SERVING AS TGF-BETA R1 KINASE INHIBITOR | Jiangsu AoSaiKang Pharmaceutical Co., Ltd. (CN) | 2021-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098171-A1 | 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS SERVING AS TGF-ßR1 KINASE INHIBITOR | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885ABCG2 1686/4885PLA2G2A 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.